New Immune-Engaging drug takes aim at Hard-to-Treat ovarian cancer
NCT ID NCT07690189
First seen Jul 08, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-stage trial tests an investigational drug called NTB-928 in women with ovarian cancer that has come back or no longer responds to standard treatments. NTB-928 is designed to direct the body's immune T cells to attack cancer cells by targeting a protein called FRα. The study aims to find a safe dose, understand how the drug moves through the body, and look for early signs that it may shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NTB-928
- What this could lead to
- If successful, this could point toward a new treatment option for ovarian cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. Side effects may limit dosing, and the drug may not show meaningful anti-cancer activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Northwell, LLC
RECRUITINGLake Success, New York, 11042, United States
-
Start Ccbd, Llc
RECRUITINGFort Worth, Texas, 76104, United States